| Literature DB >> 27406829 |
Mev Dominguez-Valentin1, Andrea Gras Navarro1, Aminur Mohummad Rahman1, Surendra Kumar2, Christèle Retière3, Elling Ulvestad4, Vessela Kristensen5, Morten Lund-Johansen6, Benedicte Alexandra Lie7, Per Øyvind Enger8, Gro Njølstad9, Einar Kristoffersen10, Stein Atle Lie11, Martha Chekenya12.
Abstract
By affecting immunological presentation, the presence of cytomegalovirus in some glioblastomas may impact progression. In this study, we examined a hypothesized role for natural killer (NK) cells in impacting disease progression in this setting. We characterized 108 glioblastoma patients and 454 healthy controls for HLA-A,-B,-C, NK-cell KIR receptors, and CMV-specific antibodies and correlated these metrics with clinical parameters. Exome sequences from a large validation set of glioblastoma patients and control individuals were examined from in silico databases. We demonstrated that the KIR allele KIR2DS4*00101 was independently prognostic of prolonged survival. KIR2DS4*00101 displayed 100% concordance with cognate HLA-C1 ligands in glioblastoma patients, but not controls. In the context of both HLA-C1/C2 ligands for the KIR2DS4 receptor, patient survival was further extended. Notably, all patients carrying KIR2DS4*00101 alleles were CMV seropositive, but not control individuals, and exhibited increased NK-cell subpopulations, which expressed the cytotoxicity receptors CD16, NKG2D, and CD94/NKG2C. Finally, healthy controls exhibited a reduced risk for developing glioblastoma if they carried two KIR2DS4*00101 alleles, where protection was greatest among Caucasian individuals. Our findings suggest that KIR2DS4*00101 may offer a molecular biomarker to identify intrinsically milder forms of glioblastoma. Cancer Res; 76(18); 5326-36. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27406829 DOI: 10.1158/0008-5472.CAN-16-1162
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701